Postdocs working in the lab of Jennifer Doudna at UC Berkeley bring the testing lab online in just three weeks.
The FDA has approved Guardant360 CDx for tumor mutation profiling in patients with any solid cancerous tumor and has also approved it as a CDx to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso (osimertinib).
The new method, called nanoproteomics, captures and measures various forms of the protein cardiac troponin I, or cTnI, a biomarker of heart damage currently used to help diagnose heart attacks and other heart diseases.
More than 40,000 HCPs consented to testing with 13% (5,523) testing positive for antibodies. The positive sample pool comprised 11,468 (28.4% of positive tests) and 3,746 physicians (9.3%).
The kinase enzyme, called TBK1, plays a central role in regulating the degradation and clearance of the huntingtin protein and introduces chemical modifications that block its aggregation.
The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad.
Custom computer programs processed millions of genetic sequences to compare the antibody repertoire from B cells, depending on whether the microbes stay in the intestine, or whether they reach the bloodstream. In both cases, the antibody repertoire is altered, but in rather different ways depending on how the exposure occurs.
TRACK will recruit 400 people diagnosed with any rare cancer, which is defined as incidence of six per 100,000 people, per year, in the U.S. The study will focus on cholangiocarcinoma and cancer of unknown primary due to the promise of precision approaches in these subsets.
Findings from the new study could point to methods for identifying diseases and predicting their behaviors that are faster, simpler, less expensive, and more accurate than current standard techniques.
Results from the early blood tests showed that those that had poor outcomes from oxygen deprivation during birth could be predicted based on changes in the expression of 855 genes in the blood shortly after birth.